Oxandrolone Update: What Patients Need to Know in 2026

If you have a prescription for oxandrolone or have taken it in the past, you may be wondering about its status in 2026. The situation is straightforward but important to understand: commercial oxandrolone no longer exists in the US market. Here's everything you need to know.

Quick Summary: Oxandrolone Availability in 2026

• Commercial status: All FDA-approved commercial oxandrolone products were withdrawn from the US market on June 28, 2023
• Legal status: Still a legal Schedule III controlled substance — can be prescribed and dispensed via compounding
• Where to get it: Licensed 503A compounding pharmacies only (not retail chains)
• Cost without insurance: Typically $150–$350 per 30-day supply (compounding fee)
• Insurance: Most plans do not cover compounded medications; coverage is very limited

Timeline: How We Got Here

Understanding the history helps explain the current situation:

• 1964: Oxandrolone first approved by the FDA and marketed as Anavar by Searle Laboratories
• 1984: FDA advisory committee finds insufficient evidence of efficacy for some approved indications
• 1989: Searle discontinues Anavar production partly due to controversy over illicit bodybuilding use
• 1995: Re-introduced as Oxandrin by Savient Pharmaceuticals after positive clinical trials
• 1990–2004: Classified as Schedule III under the Anabolic Steroids Control Act of 1990
• December 2022: FDA notifies Gemini Laboratories (brand holder) and generic manufacturers of serious safety concerns
• June 28, 2023: FDA formally withdraws approval for all oxandrolone products (Oxandrin NDA + 4 generic ANDAs)
• 2023–2026: Compounded oxandrolone becomes the only legal US source for new prescriptions

Why Did the FDA Pull Oxandrolone?

The FDA cited two main categories of concern when withdrawing oxandrolone:

1. Serious safety warnings: The prescribing information carried boxed warnings for peliosis hepatis (blood-filled liver cysts that can cause fatal internal hemorrhage), potentially fatal liver cell tumors, and blood lipid changes leading to atherosclerosis and cardiovascular disease.

2. Efficacy questions: An FDA advisory committee had concluded back in 1984 that evidence of efficacy for many of the approved indications was insufficient. Despite decades of continued prescribing, those efficacy concerns were never fully resolved to the FDA's satisfaction.

It's worth noting that the manufacturers themselves (Gemini Laboratories and Sandoz) actually requested the withdrawal — the FDA did not force it over their objections. The companies concluded it was no longer viable to maintain approval given the regulatory environment and safety profile.

Is This a Shortage or a Permanent Withdrawal?

This is a permanent market withdrawal, not a temporary shortage. There is no indication that any manufacturer intends to seek new FDA approval for commercial oxandrolone in the near future. Unless the regulatory landscape changes significantly, patients will continue to rely on compounding pharmacies indefinitely.

What Are Your Options as a Patient in 2026?

Option 1: Compounded oxandrolone. A licensed 503A compounding pharmacy can prepare oxandrolone tablets in custom strengths for your specific prescription. Requires a valid Schedule III prescription from a DEA-registered provider.

Option 2: Switch to an alternative medication. Testosterone (various forms), nandrolone decanoate, or stanozolol may serve similar therapeutic goals. Discuss with your prescriber which alternative best fits your diagnosis.

Option 3: Use medfinder. If you want to try compounded oxandrolone, medfinder contacts pharmacies on your behalf to identify which compounding pharmacies can fill your prescription — saving you the effort of calling around.

Will Commercial Oxandrolone Ever Come Back?

As of 2026, there is no public indication that any pharmaceutical company has filed or plans to file a new drug application for commercial oxandrolone in the United States. The safety concerns that drove the withdrawal remain documented and would need to be addressed in any new application. For now, compounding remains the only path. For more background, see: Why Is Oxandrolone Hard to Find in 2026?.